INSTITUTO-COORDENADAS
In the socioeconomic recovery of Europe’s main cities following the effects of the Covid-19 pandemic, a commitment to healthcare, innovation and medical research is a key element. In that regard, Barcelona and the surrounding area play a European leadership role, uniting a powerful healthcare field with a high quality scientific research network. And according to the initial conclusions of a study by Instituto Coordenadas, the city’s response to Covid-19 is an example of public-private partnership.
The response of the healthcare sector, ensuring Barcelona is a safe city, combines with the Catalan capital’s research efforts over several decades and its strength in recruiting talent for innovation and research in biotechnology and health. The city’s hospital network, for instance, has made great strides in both medicine and research during the crisis. Some of the main achievements in that regard include the work of Hospital Clínic, and its partnership with the US-based MIT research team in particular, and the Vall d’Hebron University Hospital, which has been congratulated by the World Health Organization (WHO) for managing the fight against the pandemic. Another example of Barcelona’s dominant position lies in the work of the SciTech DiploHub, an initiative that has succeeded in bringing together the field of international scientific diplomacy.
Barcelona’s public-private scientific ecosystem has also been at work during the Covid-19 threat, with around 20 initiatives placing Catalonia’s capital at the forefront in the fight against the pandemic. Examples go from top level clinical trials, such as the one carried out by Germans Trias i Pujol Research Institute (IGTP) to stop those with the virus spreading it further, to IQS’s efforts to find an inhibitor for attacking one of the receptors of Covid-19. Most recently, the expertise of three doctors from Barcelona’s ISGlobal played a key role in redressing the errors relating to the effectiveness of hydroxychloroquine as regards Covid-19, and there is also the example of the work being carried out into new treatments for eliminating cytokine storms.
Another development that has put Barcelona on the front line has been the global partnership between the city’s six cutting-edge science centres, 110 pharmaceutical companies – with their long-standing relationship with the city – and biotech businesses and start-ups based at the Barcelona Science Park (PCB). The aim of the alliance is to secure an effective antiretroviral drug for fighting Covid-19, vaccines and more effective rapid diagnostic tests.
PCB, with its 2,800 professionals, was Spain’s first science park and is home to IRB Barcelona, which is one of the research centres selected by the European Union to identify an effective vaccine, new treatments and better rapid diagnostic tests. In fact, of the 17 projects selected in Europe, five come from Barcelona and the surrounding area.
The fight against the virus has seen the whole of the local research network entering into partnership. For instance, the Barcelona Supercomputing Center (BSC) has made its Mare Nostrum supercomputer available to researchers so they can fight the pandemic using artificial intelligence and bioinformatics.
In short, this array of alliances has put Barcelona in a position of excellence on the European map of efforts to fight Covid-19.
ABOUT INSTITUTO COORDENADAS DE GOBERNANZA Y ECONOMIA APLICADA
The institute develops thought and undertakes research into the interaction between governance and applied economics in order to make constructive and decisive progress in three fundamental issues: social wellbeing, economic progress and environmental sustainability. This takes place in a context of development and evolution, unprecedented since the end of the 18th century and the beginning of the 19th century with the industrial revolution. Faithful to its founding principles of independence, non-partisanship and plurality, the institute is a proactive leader of the fusion between the essence and innovation of economic liberalisation as the best model for tackling the challenge of the present and the future in Spain, Europe and the world.
Further information: www.institutocoordenadas.com
NOTE: The information contained in this press release is a public interest summary from reports and studies based on analysis and research; expert working groups and sessions; and/or production of scientific articles by Instituto Coordenadas de Gobernanza y Economía Aplicada. The original and complete documents are for internal use and are the sole property of Instituto Coordenadas de Gobernanza y Economía Aplicada.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005751/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
